 |
 Video: What is a Stock Split?
|
|
|
| Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents. Co. markets Rubraca®, which is an oral small molecule inhibitor of poly ADP-ribose polymerase for indications specific to recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. Co.'s product candidates include: FAP-2286, a peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein; and Lucitanib, an oral potent angiogenesis inhibitor which inhibits vascular endothelial growth factor receptors 1 through 3, platelet-derived growth factor receptors alpha and beta and fibroblast growth factor receptors 1 through 3. According to our Clovis Oncology stock split history records, Clovis Oncology has had 0 splits. | |
|
Clovis Oncology (CLVS) has 0 splits in our Clovis Oncology stock split history database.
Looking at the Clovis Oncology stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Clovis Oncology shares, starting with a $10,000 purchase of CLVS, presented on a split-history-adjusted basis factoring in the complete Clovis Oncology stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
05/02/2014 |
|
| End date: |
12/20/2022 |
|
| Start price/share: |
$53.34 |
|
| End price/share: |
$0.08 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-99.85% |
|
| Average Annual Total Return: |
-52.88% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$15.00 |
|
| Years: |
8.64 |
|
|
|
|
|
